Introduction
============

Currently, the clinical management of metastatic cancer of the bone or osteoporosis targets signaling pathways associated with bone remodeling ([@b1-ol-0-0-6121]). For example, bisphosphonate (BP) inhibits osteoclast function and bone turnover to manage these diseases ([@b1-ol-0-0-6121]). Patients receiving BP treatment, including zoledronate, can develop osteonecrosis of the jaw (ONJ), specifically BP-related ONJ (BRONJ), although the relative prevalence of this is low ([@b1-ol-0-0-6121]). Denosumab, a human monoclonal antibody directed against the receptor activator of nuclear factor-κβ ligand (RANKL), has been approved as an antiresorptive agent ([@b1-ol-0-0-6121]). Denosumab inhibits the binding of RANKL to RANK, thereby reducing osteoclast formation, function and survival, which results in decreased bone resorption and increased bone density ([@b1-ol-0-0-6121]). However, studies have demonstrated that denosumab can induce ONJ, similarly to BP ([@b1-ol-0-0-6121],[@b2-ol-0-0-6121]). There is currently insufficient evidence regarding the diagnosis and treatment of denosumab-associated ONJ.

The present study reports a case of ONJ of the maxilla in an 86-year-old male who had been treated with denosumab to manage bone metastases associated with prostate cancer. To elucidate the influence of denosumab on the development of ONJ, the present study also reviewed the literature, including clinical trials ([@b3-ol-0-0-6121]--[@b10-ol-0-0-6121]) and case reports ([@b11-ol-0-0-6121]--[@b21-ol-0-0-6121]), in regards to the prevalence, clinical characteristics and management of ONJ associated with denosumab.

Case report
===========

An 86-year-old male was referred to the Department of Dentistry and Oral Surgery at the University of Fukui Hospital (Fukui, Japan) in December 2013 with bone exposure in the left upper premolar region. The bone exposure had developed over a period of 1 month. The patient had a prior history of endodontic treatment of the left upper premolar teeth during 2008 (month unknown). The patient was a non-smoker and did not drink alcohol. In addition, the patient had no history of receiving radiation therapy to the head and neck region, and his medical history included tuberculosis, myocardial infarction, hypothyroidism and prostate cancer. The patient\'s prostate cancer had been treated with high-intensity focused ultrasound therapy in November 2002 and a radical prostatectomy in January 2004. Pathological diagnosis of the surgical specimen revealed moderately differentiated adenocarcinoma of the prostate (pT3aN0M0, stage III), and hormone therapy (combined androgen blockade therapy using an anti-androgen drug and LH-RH agonist; doses unknown) was initiated in January 2004 (duration, 4 years). Due to increasing prostate-specific antigen values, the patient was treated with chemotherapy in February 2008 (including docetaxel 40 mg per patient triweekly and tegafur/uracil 200 mg/day; duration, 4 years and 10 months); skeletal metastases were identified in January 2009. The patient had been treated once with zoledronate (4 mg per patient) in January 2009, but it was discontinued due to hypocalcemia and renal dysfunction. The patient underwent 6 subcutaneous injections of 120 mg denosumab between September 2012 and March 2013 and 1 subcutaneous injection of 120 mg denosumab in December 2013.

Physical examination of the patient revealed no facial swelling or neck lymphadenopathy. No paresthesia of the left infra-orbital region was evident. An intra-oral examination revealed a 5×10 mm dehiscence of the oral mucosa in the upper left premolar region. Exposure of the underlying bone, redness and slight swelling of the surrounding gingiva were also observed; however, there was no obvious pus discharge ([Fig. 1](#f1-ol-0-0-6121){ref-type="fig"}). The patient complained of tenderness in the left infraorbital area. A panoramic radiograph revealed radiolucencies with diffuse irregularity in the left maxilla and around the apices of the left upper premolar teeth ([Fig. 2A](#f2-ol-0-0-6121){ref-type="fig"}). An axial computed tomography image (bone window setting) identified an area of low density in the left posterior maxilla and the destruction of the buccal cortical bone, indicating osteomyelitis ([Fig. 2B](#f2-ol-0-0-6121){ref-type="fig"}). A coronal image (bone window setting) demonstrated bone sequestrum in the left maxilla, perforation in the inferior wall of the maxillary sinus and sinusitis ([Fig. 2C](#f2-ol-0-0-6121){ref-type="fig"}). Bone scintigraphy revealed increased uptake of ^99m^Tc-methylene diphosphonate (MDP) from the left maxilla to part of the sinus and provided evidence of active bone turnover ([Fig. 2D](#f2-ol-0-0-6121){ref-type="fig"}). The uptake of ^99m^Tc-MDP at the sites of the upper right humerus, left scapula, sternum, chest and lumbar spine, ribs and pelvic bone indicated multiple metastatic lesions of the bone ([Fig. 2E](#f2-ol-0-0-6121){ref-type="fig"}). Over 8 weeks (from December 2013 to January 2014), the patient presented no change in the area of the exposed bone. The patient\'s history combined with the clinical and radiographic findings was consistent with ONJ and the administration of denosumab was discontinued in January 2014.

The patient refused radical surgical treatment under general anesthesia, so the exposed bone was partially removed under local anesthesia. Histological examination of 5-µm sections of the surgical sample, using light microscopy and hematoxylin and eosin staining, revealed complete osteonecrosis with empty osteocytic lacunae throughout the extent of the bone fragment ([Fig. 3A and B](#f3-ol-0-0-6121){ref-type="fig"}). *Actinomyces* colonies were observed, but no osteocytes, osteoblasts or osteoclasts were present in the histologically examined sample; there was also no sign of prostate cancer metastasis. Microbiological analysis revealed a mixed normal oral flora, including *Streptococcus*, *Neisseria* and *Corynebacterium* species, but *Actinomyces* was not identified in the microbiologically examined sample. A final diagnosis of ONJ of the maxilla was confirmed. For \>30 months (December 2013 to May 2016, the date of writing), the patient was maintained on daily chlorhexidine mouth rinses, and an antibiotic (amoxicillin 750 mg/day for 7 days) was used during periods of exacerbation (increased pain, redness and pus-containing discharge). The intraoral dehiscence remained, but the patient did not complain of pain. The patient provided written informed consent for the use of their data in the present study.

Discussion
==========

A relatively recent development for the treatment of metastatic cancer of the bone or osteoporosis has been the inhibition of RANKL, a member of the tumor necrosis factor superfamily of ligands ([@b1-ol-0-0-6121]). Denosumab is a human monoclonal antibody directed against RANKL, which inhibits the binding of RANKL to RANK, thereby inhibiting osteoclast differentiation and function ([@b1-ol-0-0-6121]).

ONJ is defined as exposed bone in the maxillofacial region that does not heal for ≥8 weeks in patients with no history of craniofacial radiation ([@b2-ol-0-0-6121],[@b22-ol-0-0-6121],[@b23-ol-0-0-6121]). ONJ was first described in patients receiving BP therapy ([@b24-ol-0-0-6121]), and an increasing number of patients with BRONJ have been reported. There has been a previous report that the use of denosumab can also lead to ONJ ([@b11-ol-0-0-6121]). The American Association of Oral and Maxillofacial Surgeons has proposed that ONJ caused by BP or denosumab is called medication-related ONJ (MRONJ) ([@b2-ol-0-0-6121]). Although the etiology and pathophysiology of MRONJ remain unclear, several potential mechanisms affecting the risk of developing ONJ have been proposed. Hypotheses include the inhibition of osteoclastic bone resorption and remodeling, inflammation and infection, inhibition of angiogenesis, soft tissue toxicity and immune dysfunction ([@b2-ol-0-0-6121]).

To elucidate the relationship between denosumab use and the development of ONJ, the results of clinical trials presenting denosumab-related ONJ were reviewed. Typically, the patients with metastatic bone cancer received monthly 120 mg denosumab injections (for 6--36 months) and ONJ was observed at a rate of 0--5% ([Table I](#tI-ol-0-0-6121){ref-type="table"}) ([@b3-ol-0-0-6121]--[@b10-ol-0-0-6121]). By contrast, the patients with osteoporosis typically received 60 mg denosumab injections every 6 months (for 12--36 months) and ONJ was observed at the rate of 0% ([@b25-ol-0-0-6121]--[@b27-ol-0-0-6121]). In a previous report, the prevalence of BRONJ was ≤10% following intravenous BP treatment for malignancy-associated bone disease and \<0.05% following oral BP treatment for osteoporosis ([@b28-ol-0-0-6121]). The greater prevalence of BRONJ in patients with malignancy was thought to be associated with the greater and more frequent dosing of BP ([@b29-ol-0-0-6121]). Thus, the high risk of ONJ in patients with cancer receiving denosumab may also be attributable to the dose and frequency of administration.

The risk of ONJ following treatment with denosumab or BP (including zoledronate, parmidronate or ibandronate) in clinical trials was reviewed ([Table II](#tII-ol-0-0-6121){ref-type="table"}) ([@b3-ol-0-0-6121],[@b4-ol-0-0-6121],[@b6-ol-0-0-6121]--[@b8-ol-0-0-6121],[@b10-ol-0-0-6121]). In patients with cancer, the prevalence of denosumab-related ONJ was 0--2% compared with 0--1.4% for BRONJ. These reports demonstrated that the prevalence of ONJ in patients treated with denosumab compared with BP is not statistically significant. Although denosumab and BP have different mechanisms of action ([@b30-ol-0-0-6121]), the prevalence of ONJ was similar in patients treated with either. Qi *et al* ([@b31-ol-0-0-6121]) reported the risk of denosumab-related ONJ in patients with cancer in a meta-analysis of seven randomized control trials. The overall prevalence of ONJ in patients with cancer receiving denosumab was 1.7% ([@b31-ol-0-0-6121]). This analysis demonstrated that the use of denosumab was associated with an increased risk of developing ONJ when compared with BP treatment or a placebo; however, the increased risk was not statistically significant between denosumab and BP treatment ([@b31-ol-0-0-6121]).

In the review of the clinical trials conducted in the present study, certain problems in the evaluation of the prevalence of denosumab-related ONJ were concerning. Firstly, several studies included patients that were currently receiving or had previously received oral BP ([@b5-ol-0-0-6121],[@b8-ol-0-0-6121],[@b9-ol-0-0-6121]). BP is an etiopathological factor for BRONJ and the effect of BP on denosumab-related ONJ was not sufficiently discussed. Secondly, in the majority of the trials reviewed, oral adverse events were adjudicated by an independent blinded committee of dental experts, but it was unclear how the oral evaluations were performed prior to and after denosumab treatment ([@b3-ol-0-0-6121],[@b4-ol-0-0-6121],[@b10-ol-0-0-6121]). Thirdly, it has been estimated that \~30% of patients with ONJ do not demonstrate bone exposure ([@b32-ol-0-0-6121]) and are defined as having stage 0 ONJ ([@b2-ol-0-0-6121]). These patients may be undiagnosed and not included in the prevalence statistics. Therefore, the actual prevalence of denosumab-related ONJ may be higher compared with that reported in the clinical trials.

To gain a better understanding of the clinical characteristics and management of denosumab-related ONJ, case reports were reviewed ([Table III](#tIII-ol-0-0-6121){ref-type="table"}) ([@b11-ol-0-0-6121]--[@b21-ol-0-0-6121]). Since 2010, 26 well-documented cases of denosumab-related ONJ have been reported in the English language literature. The reported data includes characteristics of the patients (age, gender, disease), denosumab regimen (dose, administration times), risk factors (systemic factors, medications, experience of BP treatment, local factors) ([@b1-ol-0-0-6121],[@b2-ol-0-0-6121],[@b22-ol-0-0-6121],[@b23-ol-0-0-6121],[@b33-ol-0-0-6121],[@b34-ol-0-0-6121]), clinical manifestations (site, symptoms, duration), treatments (conservative and surgical treatment, cessation of denosumab) and prognosis.

In regards to the characteristics of the patients in these case reports, the mean age of the patients with denosumab-related ONJ was 65 years (range, 49--86 years). Among the patients, 24 (92%) were aged \>55 years and only 2 patients were aged \<55 years. Denosumab-related ONJ was observed with a predilection for males (male: female ratio, 1.4:1.0). Denosumab-related ONJ was reported in 15 patients (58%) with prostatic cancer, 9 patients (34%) with breast cancer, 1 patient with colorectal cancer (4%) and 1 patient with lung cancer (4%). The regimen of denosumab treatment was reported in 25 of these patients and was typically 120 mg monthly injections.

The risk factors for ONJ in these case reports were examined in the present study, including systemic factors, medications, prior BP treatment and local factors. In the systemic factors, diabetes (n=2), obesity (n=1) and smoking (n=1) were reported. In regards to medication, 8 patients were treated with chemotherapy and 6 were treated with corticosteroid therapy. A prior history of BP treatment was specified for 2 patients, and the 2 patients additionally had past zoledronate treatment. For local factors, a history of dental procedures or conditions was reported in 25 patients. Of these patients, ONJ developed following tooth extraction in 14 patients (54%) and apical periodontitis in 2 patients (8%). ONJ most frequently occurred at the site of the dental procedure, but 6 cases occurred spontaneously without a dental procedure. In the review of clinical manifestations, the mandible was the most commonly affected site (n=17), followed by the maxilla (n=6), and 3 patients developed ONJ of the maxilla and mandible. Symptoms of ONJ were reported in 26 patients, including bone exposure (n=25), pain (n=9), redness (n=5), pus-containing discharge (n=4), swelling (n=4), tenderness (n=2) and fistula (n=2). The duration of symptoms was reported in 19 cases, with a mean duration of 5 months (range, 0.25--12 months).

In regards to the treatments for ONJ that these patients received, conservative treatments were reported in 23 patients \[administration of antibiotics in 22 patients (96%) and a mouth rinse in 21 patients (91%\]. A total of 14 (54%) were also treated surgically. The surgical treatments for ONJ included the removal of necrotic bone (n=12), debridement (n=5), incision and drainage (n=1) and tooth extraction (n=1). Descriptions about the cessation of denosumab were found for 22 patients; 19 patients (86%) had their denosumab administration discontinued and 3 patients (14%) preferred to continue denosumab therapy. The prognosis was described in 24 patients; 12 patients healed, but the other 12 patients did not.

In the present review of the reported cases, denosumab-related ONJ had a similar clinical presentation to BRONJ ([@b22-ol-0-0-6121],[@b23-ol-0-0-6121]). There was a tendency for ONJ to develop in the mandible in elderly patients. In addition, dental extraction or inflammatory dental disease was an important initiating factor. A complex medical history was also suspected to affect the prevalence of ONJ.

Denosumab-related ONJ was primarily observed in patients with prostate cancer. Qi *et al* ([@b31-ol-0-0-6121]) reported an analysis of ONJ based on tumor type, demonstrating that the prevalence of denosumab-related ONJ in patients with prostate cancer was higher compared with that in patients with non-prostate cancers. In their analysis, the median follow-up period for prostate cancer was longer compared with that for non-prostate cancer ([@b31-ol-0-0-6121]). The authors suggested that the variability in the prevalence of ONJ in the different cancer types may be due to this variation, as it is probable that the prevalence of ONJ would have increased with a longer follow-up period ([@b31-ol-0-0-6121]). A similar phenomenon has been observed in clinical trials, which demonstrated a trend toward cumulative increases in ONJ over time in patients with cancer ([@b6-ol-0-0-6121],[@b7-ol-0-0-6121]). In addition, the relatively long clinical course of prostate cancer ([@b35-ol-0-0-6121]) may affect the prevalence of denosumab-related ONJ. In the review conducted in the present study, ONJ was also observed prevalently in males. This is likely due to the fact that denosumab-related ONJ was most frequently observed in patients with prostate cancer.

Denosumab has produced excellent clinical results compared with BP for the treatment of patients with bone-associated cancer and osteoporosis, causing great increases in bone mineral density and the suppression of bone turnover markers ([@b3-ol-0-0-6121],[@b26-ol-0-0-6121]), in addition to efficacy even in patients who were previously resistant to BP treatment ([@b36-ol-0-0-6121]). In the review of case reports conducted in the present study, 2 patients transitioned from BP and developed denosumab-related ONJ. Thus, the effect of prior BP treatment should be considered as an etiopathological factor for denosumab-related ONJ. In the case reported in the present study, the patient received a single zoledronate treatment followed by denosumab therapy. Although the short duration of BP treatment in this patient was unlikely to have contributed to the development of ONJ, the possibility that BP treatment may synergistically enhance the denosumab-related inhibition of osteoclastic activity and development of ONJ should be considered.

In the literature review performed in the present study, no clear relationship between the duration of denosumab treatment and the development of denosumab-related ONJ was observed. In one case, a patient developed ONJ after receiving two 60 mg doses of denosumab ([@b14-ol-0-0-6121]), while in another, a patient developed ONJ after 36 monthly administrations of 120 mg denosumab ([@b21-ol-0-0-6121]). Due to the limited number of patients included in the present review, the accurate assessment of the association between the dose/duration of denosumab treatment and the onset of ONJ was difficult to determine. This association should be examined in a larger patient cohort.

The concept of a 'drug holiday' in patients receiving denosumab who require invasive dental treatments is an ongoing area of controversy ([@b2-ol-0-0-6121]). There are no previous studies to support or refute the strategy of stopping denosumab therapy for the prevention or treatment of MRONJ ([@b2-ol-0-0-6121]). In the review conducted in the present study, 3 patients continued on denosumab and administration was stopped in 19 patients following MRONJ. Otto *et al* ([@b37-ol-0-0-6121]) reported 2 successful cases of surgical treatment of denosumab-related ONJ. The authors recommended that any surgical intervention should be withheld until ≥4 months after cessation of denosumab treatment ([@b37-ol-0-0-6121]). By contrast, Diz *et al* ([@b12-ol-0-0-6121]) reported a case of denosumab-related ONJ due to tooth extraction 6 months after cessation of denosumab therapy. Notably, Vyas *et al* ([@b38-ol-0-0-6121]) reported a case of denosumab-related ONJ that healed within 1 month of cessation of denosumab. Thus, it is difficult to determine the appropriate period of a drug holiday for denosumab.

BP is incorporated into the mineral matrix of the bone, but denosumab has no binding affinity for the bone matrix ([@b14-ol-0-0-6121]). In terms of drug half-life, denosumab has an advantage compared with BP, with a shorter half-life of 25.4 days compared with 10--12 years, respectively ([@b39-ol-0-0-6121]). Thus, ONJ may resolve more rapidly after a drug holiday in patients taking denosumab compared with patients taking BP. Based on the pharmacokinetics of denosumab, it may be possible to place patients on an effective drug holiday prior to surgical interventions to promote bone healing. In the evaluation of bone metabolism, the measurement of bone turnover markers aids in the assessment of the patient\'s condition ([@b40-ol-0-0-6121]). Further studies using bone turnover markers are required to verify the rate of bone turnover after cessation of denosumab in patients who develop, or are at significant risk of developing, denosumab-related ONJ. Discontinuing bone antiresorptive agent therapy is an important part of the management of bone conditions ([@b41-ol-0-0-6121]). The injudicious discontinuation of denosumab therapy can lead to an increased risk of the progression of bony lesions in patients with cancer. Thus, sufficient medical consultation and discussion are appropriate prior to the cessation of denosumab treatment.

In patients with cancer that develop ONJ, the current recommendations are conservative treatment and to avoid additional invasive surgeries ([@b2-ol-0-0-6121]). In a previous report, conservative treatment (oral monitoring, oral rinses, antibiotics) led to an overall ONJ resolution rate of 36% ([@b42-ol-0-0-6121]). The resolution rate was greater in the denosumab-treated group (40.4%) compared with the zoledronate-treated group (29.7%) ([@b42-ol-0-0-6121]). This more rapid recovery is likely due to the more rapidly reversible effects of denosumab on bone turnover compared with BP ([@b42-ol-0-0-6121]).

Conservative therapy may not always lead to the complete resolution of lesions, but it can provide long-term symptomatic relief ([@b43-ol-0-0-6121]). In the case reported in the present study, the patient refused radical surgical treatment under general anesthesia and was treated with a minimal debridement of the necrotic bone followed by chlorhexidine mouth rinses and antibiotic therapy. Although the lesion did not heal, the symptoms disappeared or were manageable. The patient was satisfied with the results of the treatment, and their condition was maintained throughout the long follow-up period.

Although treatment guidelines supports the conservative management of ONJ ([@b2-ol-0-0-6121],[@b23-ol-0-0-6121]), in the review of the literature conducted in the present study, certain lesions did not respond well to conservative treatment and were thus managed surgically. Ristow *et al* ([@b44-ol-0-0-6121]) reported treatment outcomes for MRONJ, with the success rates of conservative treatment regimens ranging from between \<20% and \>50%, which is significantly lower compared with the success rates of \>85% reported for surgical approaches ([@b44-ol-0-0-6121]). The authors suggested that surgical interventions should be considered for all stages of MRONJ ([@b44-ol-0-0-6121]). Although surgery is an option for the resolution of non-responsive ONJ lesions, certain cases that were reviewed in the present study did not heal despite surgical treatments ([@b14-ol-0-0-6121],[@b15-ol-0-0-6121]). These results indicate that the appropriate treatment plan for ONJ must be decided in accordance with the situation and condition of the individual patient.

In the present case report, *Actinomyces* colonies were observed in the histological examination, but not in the microbiological analysis. Recent studies have revealed the presence of *Actinomyces* colonies in biopsy material from patients with MRONJ, suggesting that these bacteria contribute to MRONJ-associated infections ([@b2-ol-0-0-6121],[@b45-ol-0-0-6121],[@b46-ol-0-0-6121]). Members of the *Actinomyces* genus are filamentous, gram-positive and anaerobic bacteria that typically colonize the mouth, colon and vagina. The most common disease caused by these bacteria is cervicofacial actinomycosis ([@b47-ol-0-0-6121]), which presents as a soft tissue induration with abscesses and multiple fistula. Histopathologically, *Actinomyces* is identified primarily by its characteristic formation of sulfur granules ([@b45-ol-0-0-6121]). The diagnosis of actinomycosis is based on microbiological and/or histological analysis ([@b48-ol-0-0-6121],[@b49-ol-0-0-6121]). The results of the two examinations often differ from one another ([@b49-ol-0-0-6121]). The microbiological identification of *Actinomyces* is difficult because the anaerobic processing of the specimens is strict ([@b48-ol-0-0-6121]), requiring careful culture, preferably when the patient has received no antibiotics for 7--10 days ([@b50-ol-0-0-6121]). Furthermore, the growth rate of *Actinomyces* bacteria is slow ([@b48-ol-0-0-6121]). Thus, false negative results are frequently caused by the taking or transporting of specimens for studies ([@b49-ol-0-0-6121]). By contrast, the tissue samples for histological examination do not require any special treatment and the diagnosis of actinomycosis relies only on the detection of sulfur granules ([@b48-ol-0-0-6121]). Therefore, the final diagnosis has a tendency to depend on histopathological confirmation ([@b51-ol-0-0-6121]). This explains the discrepancy in the results of the case reported in the current study. It remains unclear whether *Actinomyces* organisms trigger MRONJ or whether MRONJ triggers secondary infection with these bacteria. The role of these organisms in the development MRONJ requires further investigation.

In conclusion, the prevalence of denosumab-related ONJ is low, but remains potentially severe complication of denosumab treatment. Thus, the management of denosumab-related ONJ represents a challenge for clinicians. Since denosumab may offer superior results compared with BP for the treatment of metastatic cancer to the bone or osteoporosis, the use of denosumab is expected to increase in the near future. Clinicians should also be aware of the recognized risk factors for denosumab-related ONJ, in order to aid in its diagnosis. The results of the current study indicate that patients treated with denosumab should receive prophylactic treatment to maintain their oral health prior to, during and after denosumab treatment. Invasive dental procedures should also be avoided during and after denosumab use. If a patient develops denosumab-related ONJ, conservative therapy is the mainstay; however, surgery is an option for non-responsive ONJ lesions. The contribution of denosumab to the development of ONJ remains unclear; further studies specifically designed to assess the prevalence of ONJ in larger cohorts over long observation periods are required. Further research on animal models is also needed to elucidate the underlying mechanism of denosumab-related ONJ. Analyses of the required length of drug holiday and the timing of surgical intervention in denosumab-related ONJ by measuring the levels of bone turnover markers are warranted. Further studies remain necessary to establish guidelines for the prevention and effective treatment of denosumab-related ONJ.

![Clinical appearance of the denosumab-related osteonecrosis of the jaw. An intraoral view revealed exposed necrotic bone in the left upper maxilla with redness of the mucosa (indicated by the arrowhead).](ol-14-01-0127-g00){#f1-ol-0-0-6121}

![Imaging findings. (A) A panoramic radiograph revealed radiolucencies with diffuse irregularity in the left maxilla and around the apices of the left upper premolar teeth (indicated by the arrowheads). (B) An axial CT (bone window setting) identified an area of low density in the left posterior maxilla and the destruction of the buccal cortical bone (indicated by the arrowhead). (C) A coronal CT (bone window setting) demonstrated bone sequestrum in the left maxilla (indicated by the arrowhead), a perforation in the inferior wall of the maxillary sinus and sinusitis. Bone scintigraphy revealed (D) increased uptake of ^99m^Tc-MDP from the left maxilla to part of the sinus, providing evidence of active bone turnover, and (E) uptake of ^99m^Tc-mMDP at the upper right humerus, left scapula, sternum, chest and lumbar spine, ribs, pelvic bone, indicating multiple metastatic lesions in the bone. CT, computed tomography.](ol-14-01-0127-g01){#f2-ol-0-0-6121}

![Histological findings from hematoxylin and eosin staining. (A) Histological examination revealed necrotic bone with adherent bacteria and actinomycotic colonies. Scale bar, 200 µm. (B) No osteoblasts, osteocytes or osteoblasts were observed. Scale bar, 100 µm.](ol-14-01-0127-g02){#f3-ol-0-0-6121}

###### 

Clinical trials presenting denosumab-related ONJ.

                                                                                                      Denosumab regimen                         Prior treatment with BP and route of administration                                                                                                                           
  --------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------- ----------------------------------------------- --------------------------------------------------- ------- ----- ----- -----
  Breast cancer with bone metastases (3)                                                              30, 120, or 180 mg QM, 60 or 180 mg Q3M   24 weeks                                              No                                              ND                                                    211     0   0.0   ND
  Prostate cancer, breast cancer or other neoplasms with bone metastases (4)                          180 mg QM or Q3M                          25 weeks                                              ND                                              ND                                                    73      0   0.0   ND
  Non-metastatic prostate cancer (5)                                                                  60 mg Q6M                                 36 months                                             No pretreatment within 5 years was acceptable   No pretreatment of \>3 years was acceptable           731     0   0.0   Yes
  Bone metastases with breast cancer (6)                                                              120 mg QM                                 34 months                                             No                                              No                                                  1,020   20    2.0   Yes
  Bone metastases of advanced cancer (excluding breast and prostate cancer) or multiple myeloma (7)   120 mg QM                                 34 months                                             No                                              ND                                                    878   10    1.1   Yes
  Bone metastases in males with castration-resistant prostate cancer (8)                              120 mg QM                                 ND                                                    No                                              Previous oral BP use for osteoporosis was allowed     943   22    2.0   Yes
  Males with non-metastatic castration-resistant prostate cancer (9)                                  120 mg QM                                 24 months                                             No                                              Less than 3 years was acceptable                      720   33    5.0   Yes
  Lung cancer and bone metastases (10)                                                                120 mg QM                                 ND                                                    No                                              ND                                                    406     3   0.7   ND

Oral adverse events were adjudicated by an independent blinded committee of dental experts. BP, bisphosphonate; ND, not described; ONJ, osteonecrosis of the jaw; QM, administered monthly; Q3M administered every 3 months; Q6M administered every 6 months.

###### 

Comparison of risk of developing ONJ between patients treated with denosumab and BPs in clinical trials.

  Study                                                                                               Drug                                       No. of patients   No. ONJ cases   ONJ rate (%)   Statistical evaluation
  --------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------- --------------- -------------- --------------------------
  Breast cancer with bone metastasis (3)                                                              Denosumab                                    211               0             0.0            ND
                                                                                                      Zoledronate, Parmidronate or Ibandronate     43                0             0.0            
  Prostate cancer, breast cancer or other neoplasms with bone metastases (4)                          Denosumab                                    73                0             0.0            ND
                                                                                                      Zoledronate, Parmidronate                    35                0             0.0            
  Bone metastases with breast cancer (6)                                                              Denosumab,                                 1,020             20              2.0            Not significant (P=0.39)
                                                                                                      Zoledronate                                1,013             14              1.4            
  Bone metastases of advanced cancer (excluding breast and prostate cancer) or multiple myeloma (7)   Denosumab,                                   878             10              1.1            Not significant (P=1.00)
                                                                                                      Zoledronate                                  878             11              1.3            
  Bone metastases in males with castration-resistant prostate cancer (8)                              Denosumab,                                   943             22              2.0            Not significant (P=0.09)
                                                                                                      Zoledronate                                  945             12              1.0            
  Lung cancer and bone metastases (10)                                                                Denosumab,                                   406               3             0.7            ND
                                                                                                      Zoledronate                                  395               3             0.8            

The statistical evaluation was performed by the authors who conducted the clinical trials. ND, not described; ONJ, osteonecrosis of the jaws.

###### 

Reported cases of denosumab-related ONJ in the English language literature (n=26).

  Characteristics                                                                                  Value
  ------------------------------------------------------------------------------------------------ --------------
  Age, range (mean), years                                                                         49--86 (65)
  Gender ratio, M:F                                                                                1.4:1
  Type of disease, no. of patients                                                                 
    Prostatic cancer                                                                               15
    Breast cancer                                                                                    9
    Colorectal cancer                                                                                1
    Lung cancer                                                                                      1
  Denosumab regimen                                                                                
    Dose, mg, no. of patients (n=25^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                  
    120                                                                                            23
    60                                                                                               2
    Administration time, range (mean) months (n=22^[a](#tfn2-ol-0-0-6121){ref-type="table-fn"}^)   2--36 (13)
  Risk factors for ONJ, no. of patients                                                            
    Systemic factors (n=23^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                           
    Diabetes                                                                                         2
    Obesity                                                                                          1
    Smoking                                                                                          1
  Medications (n=23^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                                  
    Chemotherapy                                                                                     8
    Corticosteroid therapy                                                                           6
  Prior BP treatment (n=9^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                              2
  Local factors (n=25^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                                
    Tooth extraction                                                                               14
    Apical periodontitis                                                                             2
  Clinical manifestations, no. of patients (n=26^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)     
    Mandible                                                                                       17
    Maxilla                                                                                          6
    Maxilla and mandible                                                                             3
  Symptom, no. of patients (n=26^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                     
    Bone exposure                                                                                  25
    Pain                                                                                             9
    Redness                                                                                          5
    Pus discharge                                                                                    4
    Swelling                                                                                         4
    Tenderness                                                                                       2
    Fistula                                                                                          2
  Duration of symptoms, range (mean) months (n=19^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)    0.25--12 (5)
  Treatment, no. of patients                                                                       
    Conservative treatment (n=23^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                     
      Antibiotics                                                                                  22
      Mouth rinse                                                                                  21
  Surgical treatment (n=16^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                           
    Removal of necrotic bone                                                                       12
    Debridement                                                                                      5
    Incision and drainage                                                                            1
    Tooth extraction                                                                                 1
  Cessation of denosumab (n=22^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                       
    Yes                                                                                            19
    No                                                                                               3
  Prognosis, no. of patients (n=24^[a](#tfn3-ol-0-0-6121){ref-type="table-fn"}^)                   
    Healed                                                                                         12
    Unhealed                                                                                       12

Documented cases in the literature (11--21). M, male; F, female; BP, bisphosphonate; ND, not described; ONJ, osteonecrosis of the jaw.
